These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 35850986

  • 1. Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis.
    Kurosawa Y, Ito S, Sakai S, Hasegawa E, Kobayashi D, Abe A, Otani H, Nakazono K, Murasawa A, Narita I, Ishikawa H.
    Intern Med; 2022; 61(14):2117-2125. PubMed ID: 35850986
    [Abstract] [Full Text] [Related]

  • 2. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
    Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K.
    Mod Rheumatol; 2016; 26(1):24-8. PubMed ID: 26140464
    [Abstract] [Full Text] [Related]

  • 3. Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies.
    Hayashi M, Kobayakawa T, Takanashi T, Yamazaki H, Ishikawa H, Kanamono T.
    Clin Rheumatol; 2013 Jul; 32(7):961-7. PubMed ID: 23397148
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
    Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Baker D, Ishii Y, Yoshinari T, GO-FORTH study group.
    Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
    [Abstract] [Full Text] [Related]

  • 6. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S, Hsia EC.
    J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
    [Abstract] [Full Text] [Related]

  • 7. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG, Halilovic J, Stan-Ugbene O.
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [Abstract] [Full Text] [Related]

  • 8. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC.
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
    [Abstract] [Full Text] [Related]

  • 9. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [Abstract] [Full Text] [Related]

  • 10. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [Abstract] [Full Text] [Related]

  • 11. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [Abstract] [Full Text] [Related]

  • 12. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, TEAR Investigators.
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
    Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D.
    Clin Rheumatol; 2014 Sep; 33(9):1239-46. PubMed ID: 25005327
    [Abstract] [Full Text] [Related]

  • 14. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
    Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, Noonan L, Lu J, Xu Z, Leu J, Baker D, Bingham CO, GO-FURTHER investigators.
    Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
    [Abstract] [Full Text] [Related]

  • 16. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, Murphy FT, Wu Z, Parasuraman S, Rahman MU.
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [Abstract] [Full Text] [Related]

  • 17. Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy.
    Kitamura N, Kobayashi H, Nagasawa Y, Sugiyama K, Tsuzuki H, Tanikawa Y, Ikumi N, Okada Y, Takahashi Y, Asai S, Tamura N, Ogasawara M, Kawamoto T, Kuwatsuru R, Tamaki H, Kidoguchi G, Tateishi M, Kimura M, Mochida Y, Harigane K, Shimazaki T, Koike T, Tanimura K, Kataoka H, Amano K, Yasuoka H, Takei M.
    Int J Rheum Dis; 2023 Jun; 26(6):1058-1066. PubMed ID: 37058849
    [Abstract] [Full Text] [Related]

  • 18. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [Abstract] [Full Text] [Related]

  • 20. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.